Study Summary
The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Interested in this trial?
Submit an InquiryInterventions
CD19 CAR-T-cellsBIOLOGICAL
One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.
TocilizumabDRUG
Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Belarussian Research Center for Pediatric Oncology, Hematology and Immunology | Minsk | Minsk Oblast | Belarus |